Skip to Content

Toripalimab (Loqtorzi®) for Recurrent or Metastatic Nasopharyngeal Carcinoma

Download PQI pdf 0.27MB

Last Updated: December 5, 2024

By: Shirin Khorashadi, PharmD, BCOP | Deborah J. Wong, MD, PhD | Hyu Kang, MD, MPH, FACP

About this PQI

The purpose of this PQI is to discuss clinical considerations for the use of toripalimab (Loqtorzi®) for treatment of recurrent, locally advanced nasopharyngeal carcinoma or metastatic nasopharyngeal carcinoma (RM-NPC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI